Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/5/2010

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2010.

On November 2, Cadence announced that the U.S. Food and Drug Administration (FDA) approved OFIRMEV™ (acetaminophen) injection for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

"We believe that there is a clear need for OFIRMEV in the U.S., as the classes of IV analgesics available to treat acute pain – opioids and NSAIDS – are associated with significant side effects. OFIRMEV is an important new treatment option that provides patients with significant pain relief while reducing opioid consumption," said Ted Schroeder, President and CEO of Cadence. "The approval of OFIRMEV marks Cadence's transition into a commercial enterprise poised to support the successful launch of our first product early in the first quarter of 2011."

Financial ResultsFor the three months ended September 30, 2010, Cadence reported a net loss of $11.7 million, or $0.23 per share, compared to a net loss of $11.4 million, or $0.23 per share, for the comparable period in 2009. For the nine months ended September 30, 2010, Cadence reported a net loss of $37.9 million, or $0.75 per share, compared to a net loss of $30.2 million, or $0.63 per share, for the comparable period in 2009.

Operating expenses for the three months ended September 30, 2010 decreased $0.2 million to $11.1 million, from the $11.3 million reported for the same period in 2009. This decrease was primarily a result of lower research and development spending and ge
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo ... collection of bamboo mats ; the new models are ... , According to the sales manager of BambooFlooringChina.com, Bamboo ... highly renewable resource. Their bamboo mats are 100% made from ... from natural bamboo with caramel bamboo strips. , ...
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... SATURDAY, Nov. 22, 2014 (HealthDay News) -- The wide ... can pose a threat for people with food allergies, ... there are so many types of food allergies that ... over the holidays," Dr. Guha Krishnaswamy, director of allergy ... said in a hospital news release. "If you ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new collection ... the company has also offered an attracting discount on ... supplier of wedding dresses, UWDress.com is good at manufacturing ... guest gowns are provided over 20 colors, which have ... is famous for high quality. Therefore, its sales increased ...
(Date:11/22/2014)... Developers and plugin specialist of Final Cut Pro ... Model bringing the impossible to FCPX from Pixel ... obj files to FCPX enabling 3d Model editing,” said Christina ... professional and armature, FCPX 3D Model is a definite game ... Cut Pro X users to upload and control 3D objects ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2
... ... and navigation enhancement XML API. , ... (PRWEB) May 27, 2010 -- Smartlogic has released a ... websites or in enterprise information management systems, using Semaphore,s search and navigation enhancement XML ...
... Helicobacter pylori , which lives in the human stomach ... like a corkscrew, or helix. For years researchers have hypothesized ... survive and thrive within the stomach,s acid-drenched environment, ... the first time, researchers at Fred Hutchinson Cancer Research Center ...
... Schrader had it all: steady job, a wife, and two ... morethat is, more children. Taking steps to keep his nuclear ... was back on the golf course the next afternoon. ... that followed Schrader would ultimately revisit the issue of having ...
... mood of those with sensitivities worsened when exposed to ... season may not mean just the inevitable coughing, sneezing ... , Researchers reported that finding at the American Psychiatric ... "Depression is a very common disorder and allergies are ...
... , ... announced that they have now added 7,000 stores in under five months of operation. The ... 100-200 new comments per day and 500 votes per day, making it one of the ... ...
... tying genes to common tumors may be invalid, researchers ... sample sizes may undercut the reliability of recent genome ... a Greek-American analysis cautions. , The observation is the ... harnessed technological innovations in so-called "whole genome sequencing" to ...
Cached Medicine News:Health News:Smartlogic Demonstrates Improved User Search, Find and Navigation with Semaphore Open Semantic Platform 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 3Health News:Robotic-assisted vasectomy reversal offers greater chance of fatherhood 2Health News:Allergies Might Trigger Depression 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Genes' Link to Certain Cancers Questioned 2
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: